SynthesisPloS one2014
Meta-analysis on prevalence and attribution of human papillomavirus types 52 and 58 in cervical neoplasia worldwide.
Synthesis in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Worldwide burden of cervical human papillomavirus (HPV) in women over 50 years with abnormal cytology: a systematic review and meta-analysis.BMJ global health · 2025Pooled it
- Human Papillomavirus Positivity and Genotype Distribution Among Korean Females: A Large-Scale Laboratory-Based Analysis.Journal of clinical medicine · 2026Article
- Article
- HPV epidemiologic study in Bengbu, China, involving 123,808 women, 2014-2023.Virology journal · 2026Article
- An epidemiological survey of HPV infection among women in Southern Hebei, China.Virology journal · 2026Article
- Genotype-Specific HPV mRNA Triage Improves Colposcopy Efficiency Compared with Cytology and ATHENA-Derived Triage: A Population-Based Study of HPV DNA-Positive Women.Pathogens (Basel, Switzerland) · 2026Article
- Optimization of cultivation strategies for production of recombinant human papillomavirus type 58 major capsid protein L1 in Hansenula polymorpha.Bioresources and bioprocessing · 2026Article
- Prevalence and genotype distribution of high-risk human papillomavirus infections among women in selected communities in the Philippines: Results of the defeat HPV study.Journal of virus eradication · 2026Article
- Association between multiple infection patterns of HPV33 and the risk of cervical carcinogenesis.Frontiers in microbiology · 2026Article
- Human papillomavirus (HPV) genotypes extended prevalence in the female population from a city in Northern Chile.BMC women's health · 2025Article
- Patterns of Co-infection of HPV52 With Other HPV Genotypes and Their Risks of Cervical Precancer and Carcinoma.Journal of medical virology · 2025Article
- Persistently high prevalence of HPV16 and rising prevalence of non-16/18 HR-HPV genotypes in cervical precancer and cancer in Latvia in 2016-2024 shape the severity of cervical disease.Frontiers in oncology · 2025Article
- Global pattern of persistent human papillomavirus infection in female genital tract: An update system review and meta-analysis.iScience · 2024Article
- Triage performance of PAX1Clinical epigenetics · 2024Article
- Prevalence of human papillomavirus genotypes in women of different ethnicity from rural northwestern Ecuador.BMC global and public health · 2024Article
- Changes in the Incidence and Human Papillomavirus-Positive Portion of Oropharyngeal Squamous Cell Carcinoma in Hong Kong.Cancers · 2024Article
- Distribution of human papilloma virus genotypes and treatment outcomes in definitive radiotherapy for cervical cancer.Journal of radiation research · 2023Article
- Cost-Effectiveness Analysis of HPV Extended versus Partial Genotyping for Cervical Cancer Screening in Singapore.Cancers · 2023Article
- Characteristics of human papillomavirus infection among females and the genetic variations of HPV18 and HPV58 in Henan province, China.Scientific reports · 2023Article
- Relative distribution of HPV genotypes in histological cervical samples and associated grade lesion in a women population over the last 16 years in Burgundy, France.Frontiers in medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo estimate the prevalence and attribution of two non-vaccine-covered HPV types (HPV52 and HPV58) across the world.
methodsMeta-analysis on studies reported in English and Chinese between 1994 and 2012.
resultsThe pooled prevalence and attribution rates of HPV52 and HPV58 in invasive cervical cancers were significantly higher in Eastern Asia compared to other regions (HPV52 prevalence: 5.7% vs. 1.8-3.6%, P<0.001; HPV52 attribution: 3.7% vs. 0.2-2.0%; HPV58 prevalence: 9.8% vs. 1.1-2.5%, P<0.001; HPV58 attribution: 6.4% vs. 0.7-2.2%, P<0.001). Oceania has an insufficient number of studies to ascertain the prevalence of HPV52. Within Eastern Asia, the attribution of HPV58 to invasive cervical cancer was 1.8-fold higher than that of HPV52. Similarly, HPV52 and HPV58 shared a higher prevalence and attribution among cervical intraepithelial neoplasia in Eastern Asia. In contrast to the classical high-risk type, HPV16, the prevalence and attribution of HPV52 and HPV58 decreased with increasing lesion severity. Thus, HPV52 and HPV58 behave as an "intermediate-risk" type.
conclusionThe attribution of HPV52 and HPV58 to cervical intraepithelial neoplasia and invasive cancer in Eastern Asia were respectively 2.5-2.8 and 3.7-4.9 folds higher than elsewhere. Changes in the attributed disease fraction can serve as a surrogate marker for cross-protection or type replacement following widespread use of HPV16/18-based vaccines. This unique epidemiology should be considered when designing HPV screening assays and vaccines for Eastern Asia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.